3Adelsberger H,Quasthoff S,Grosskreutz J,et al.The chemotherapeutic oxaliplatin alters voltage-gated Na(+)channel kinetics on rat sensory neurons[J].Eur J Pharmacol,2000,406(1):25-32
4Sarah Taieb, Louis Descos, Gilles Freyer, et al. Lhermitte sign and urinary retention-atypical presentation of oxaliplatin neurotoxicity in four patients[J]. Cancer, 2002,94(9) : 2434 - 2440.
5Misset JL. Oxaliplatin in practice [ J ] . Br J Cancer, 1998, 77(Suppl 4):S4- S7.
6Graham MA, Lockwood GF, Greenslade D, et al. Clinical pharmacokinetics of oxaliplatin; a critical review[ J ] . Clin Cancer Res ,2000,6(4) : 1205 - 1218.
7Levi F, Metzger G, Massari C, et al. Oxaliplatin: pharmacokinetics and chronopharmacological aspeets[J]. Clin Pharmacokinet,2000,38(1) : 1 - 21.
8Luo FR, Wyrick SD, Charley SG. Biotransformations of oxaliplatin in rat blood in vitro[J] .J Biochem Mol Toxicol ,1999 ,13(3-4):159- 169.
9Gamelin E, LeBouil A, Boisdron-celle M, et al. Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluomuracil in colorectal cancer patients[J]. Clin Cancer Res, 1997,3(6) :891 - 899.
10Raymond E, Chaney SG, Taamma A, et al. Oxaliplatin: a review of preclinical and clinical studies [ J ]. Ann Oncol, 1998,9 ( 10 ) :1053- 1071.
